Total Payments
$35,730
2024 Payments
$15,376
Companies
46
Transactions
227
Payment Breakdown by Category
Consulting$27,791 (77.8%)
Food & Beverage$7,376 (20.6%)
Travel$487.70 (1.4%)
Education$74.39 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,791 | 14 | 77.8% |
| Food and Beverage | $7,376 | 207 | 20.6% |
| Travel and Lodging | $487.70 | 1 | 1.4% |
| Education | $74.39 | 5 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc | $8,850 | 5 | $0 (2024) |
| GlaxoSmithKline, LLC. | $5,850 | 3 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,935 | 2 | $0 (2023) |
| ABBVIE INC. | $4,189 | 35 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,342 | 24 | $0 (2024) |
| Celgene Corporation | $3,031 | 5 | $0 (2019) |
| CSL Behring | $600.00 | 1 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $548.26 | 6 | $0 (2023) |
| Amgen Inc. | $456.83 | 13 | $0 (2020) |
| Lilly USA, LLC | $380.18 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,376 | 19 | Kiniksa Pharmaceuticals International, plc ($8,850) |
| 2023 | $5,556 | 11 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,820) |
| 2022 | $3,149 | 7 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,115) |
| 2021 | $282.33 | 4 | Novartis Pharmaceuticals Corporation ($164.73) |
| 2020 | $442.58 | 18 | Janssen Scientific Affairs, LLC ($105.33) |
| 2019 | $1,618 | 46 | AbbVie, Inc. ($500.29) |
| 2018 | $7,653 | 62 | AbbVie, Inc. ($3,051) |
| 2017 | $1,653 | 60 | Horizon Pharma plc ($237.16) |
All Payment Transactions
227 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $126.66 | General |
| Category: Dermatology | ||||||
| 10/08/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 10/03/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $93.56 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $34.32 | General |
| 09/04/2024 | Kiniksa Pharmaceuticals International, plc | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 09/04/2024 | Kiniksa Pharmaceuticals International, plc | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 08/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $149.05 | General |
| Category: Neuropsychiatry | ||||||
| 06/13/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 06/04/2024 | Kiniksa Pharmaceuticals International, plc | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 05/21/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: IMMUNOLOGY | ||||||
| 05/02/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $32.15 | General |
| Category: NEUROSCIENCE | ||||||
| 04/06/2024 | Kiniksa Pharmaceuticals International, plc | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 03/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: NEUROSCIENCE | ||||||
| 03/13/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 03/07/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: NEUROSCIENCE | ||||||
| 01/19/2024 | Kiniksa Pharmaceuticals International, plc | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 01/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $130.95 | General |
| Category: Immunology | ||||||
| 01/17/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Analgesic | ||||||
| 11/29/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.88 | General |
| Category: Neuropsychiatry | ||||||
| 11/16/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $32.10 | General |
| Category: NEUROSCIENCE | ||||||
| 07/24/2023 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $118.60 | General |
| Category: Immunology | ||||||
| 07/07/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| 05/24/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $116.48 | General |
| Category: Dermatology | ||||||
About Dr. Robert Fox, MD
Dr. Robert Fox, MD is a Internal Medicine healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1740305432.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Fox, MD has received a total of $35,730 in payments from pharmaceutical and medical device companies, with $15,376 received in 2024. These payments were reported across 227 transactions from 46 companies. The most common payment nature is "Consulting Fee" ($27,791).
Ad
Practice Information
- Specialty Internal Medicine
- Location San Diego, CA
- Active Since 03/20/2007
- Last Updated 10/13/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1740305432
Products in Payments
- COSENTYX (Biological) $833.48
- Humira (Biological) $508.04
- RAYOS (Drug) $364.36
- Trintellix (Drug) $338.60
- Enbrel (Biological) $306.53
- COSENTYX (Drug) $243.14
- UBRELVY (Drug) $237.11
- TREMFYA (Drug) $223.93
- Tremfya (Drug) $197.51
- INGREZZA (Drug) $197.48
- XIIDRA (Drug) $164.61
- Prolia (Biological) $150.30
- QULIPTA (Drug) $144.51
- NORTHERA (Drug) $142.08
- Horizant (Drug) $139.20
- Bimzelx (Biological) $130.95
- OLUMIANT (Drug) $129.65
- Skyrizi (Biological) $124.98
- Sotyktu (Drug) $121.92
- BELSOMRA (Drug) $114.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Diego
Dr. Bob Geng, M.d, M.D
Internal Medicine — Payments: $3.0M
Internal Medicine $3.0M
Dr. Hatim Husain, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Dr. Steven Edelman, M.d, M.D
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Dr. Gary Firestein, M.d, M.D
Internal Medicine — Payments: $902,808
Internal Medicine $902,808
Dr. Adam Zweig, Md, MD
Internal Medicine — Payments: $385,670
Internal Medicine $385,670
Dr. James Breitmeyer
Internal Medicine — Payments: $362,929
Internal Medicine $362,929